📊 NKTR Key Takeaways
Is Nektar Therapeutics (NKTR) a Good Investment?
Nektar Therapeutics is in severe financial distress with collapsing revenue (-43.9% YoY), unsustainable cash burn (-$208.7M FCF), and critically depleted liquidity ($15.1M cash against -$208.5M operating cash outflow). The company will exhaust cash reserves within weeks at current burn rates, creating imminent refinancing risk with a leveraged balance sheet (1.49x debt/equity).
Fundamentals deteriorated sharply with revenue down 43.9% YoY, a near-zero gross margin, and deeply negative operating and net margins, signaling an unsustainable core model. Cash burn of $208.5M against only $15.1M in cash and leverage of 1.49x D/E create acute financing and going-concern risk. Without rapid improvement in gross margin and revenue or material cost restructuring, external financing or distress is likely.
Why Buy Nektar Therapeutics Stock? NKTR Key Strengths
- Adequate current ratio of 4.97x provides near-term liquidity buffer
- Company retains $55.2M in quarterly revenue from existing operations
- Total equity of $89.8M provides some balance sheet cushion
- Strong current and quick ratios (4.97x) support near-term payables coverage
- Very low capex ($171K) implies operational flexibility and low capital intensity
- Assets exceed liabilities with positive book equity ($89.8M)
NKTR Stock Risks: Nektar Therapeutics Investment Risks
- Critical liquidity crisis: $15.1M cash against -$208.5M quarterly operating cash burn
- Revenue collapse of 43.9% YoY indicates fundamental demand weakness for products
- Extreme operating losses (-253.7% margin) with near-zero gross margins (1.1%) suggests core business unprofitability
- High debt burden ($133.5M) limits refinancing options and may trigger covenants
- Negative free cash flow of -$208.7M is unsustainable; refinancing risk is acute
- Severe cash burn (OCF -$208.5M) versus limited cash ($15.1M) threatens runway
- Structural unprofitability with 1.1% gross margin and -253.7% operating margin
- Elevated leverage (Debt/Equity 1.49x) and no interest coverage increase refinancing risk
Key Metrics to Watch
- Cash position and burn rate trajectory - solvency indicator
- Revenue stabilization and YoY growth trend - business viability
- Debt covenant compliance and refinancing announcements - bankruptcy risk
- Gross margin improvement - product profitability
- Operating cash flow (burn rate/runway)
- Revenue growth and gross margin trajectory
Nektar Therapeutics (NKTR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.97x current ratio provides a solid financial cushion.
NKTR Profit Margin, ROE & Profitability Analysis
NKTR vs Healthcare Sector: How Nektar Therapeutics Compares
How Nektar Therapeutics compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nektar Therapeutics Stock Overvalued? NKTR Valuation Analysis 2026
Based on fundamental analysis, Nektar Therapeutics shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nektar Therapeutics Balance Sheet: NKTR Debt, Cash & Liquidity
NKTR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nektar Therapeutics's revenue has declined by 36% over the 5-year period, indicating business contraction. The most recent EPS of $-8.68 indicates the company is currently unprofitable.
NKTR Revenue Growth, EPS Growth & YoY Performance
NKTR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $11.8M | -$35.5M | $-1.87 |
| Q2 2025 | $11.2M | -$41.6M | $-2.95 |
| Q1 2025 | $10.5M | -$36.8M | $-0.19 |
| Q3 2024 | $24.1M | -$37.1M | $-0.18 |
| Q2 2024 | $20.5M | -$51.1M | $-0.25 |
| Q1 2024 | $21.6M | -$36.8M | $-0.19 |
| Q3 2023 | $23.6M | -$45.8M | $-0.24 |
| Q2 2023 | $20.5M | -$51.1M | $-0.27 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Nektar Therapeutics Dividends, Buybacks & Capital Allocation
NKTR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nektar Therapeutics (CIK: 0000906709)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NKTR
What is the AI rating for NKTR?
Nektar Therapeutics (NKTR) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 89% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NKTR's key strengths?
Claude: Adequate current ratio of 4.97x provides near-term liquidity buffer. Company retains $55.2M in quarterly revenue from existing operations. ChatGPT: Strong current and quick ratios (4.97x) support near-term payables coverage. Very low capex ($171K) implies operational flexibility and low capital intensity.
What are the risks of investing in NKTR?
Claude: Critical liquidity crisis: $15.1M cash against -$208.5M quarterly operating cash burn. Revenue collapse of 43.9% YoY indicates fundamental demand weakness for products. ChatGPT: Severe cash burn (OCF -$208.5M) versus limited cash ($15.1M) threatens runway. Structural unprofitability with 1.1% gross margin and -253.7% operating margin.
What is NKTR's revenue and growth?
Nektar Therapeutics reported revenue of $55.2M.
Does NKTR pay dividends?
Nektar Therapeutics does not currently pay dividends.
Where can I find NKTR SEC filings?
Official SEC filings for Nektar Therapeutics (CIK: 0000906709) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NKTR's EPS?
Nektar Therapeutics has a diluted EPS of $-9.73.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NKTR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Nektar Therapeutics has a STRONG SELL rating with 89% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NKTR stock overvalued or undervalued?
Valuation metrics for NKTR: ROE of -182.6% (sector avg: 15%), net margin of -297.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NKTR stock in 2026?
Our dual AI analysis gives Nektar Therapeutics a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NKTR's free cash flow?
Nektar Therapeutics's operating cash flow is $-208.5M, with capital expenditures of $171.0K. FCF margin is -377.8%.
How does NKTR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -297.1% (avg: 12%), ROE -182.6% (avg: 15%), current ratio 4.97 (avg: 2).